Lancaster General Hospital
Acute Care Hospitals · Voluntary non-profit - Private
555 North Duke Street
Lancaster, PA 17602
- Emergency services
- Medicare overall rating: 5 of 5 stars
At a glance
- Clinicians who list this hospital
- 1,939
- Physicians (MD and DO)
- 1,160
- Residents and fellows in training (full-time equivalents, fiscal year 2025)
- 45
- Medical groups
- 15+
Quality and patient experience
- Medicare overall rating (of 5)
- 5
- Patient survey rating (of 5)
- 3
- Patients who would definitely recommend it (national average 71%)
- 71%
Compared with the national rate
| Measures | Better | Same | Worse |
|---|---|---|---|
| Deaths after treatment | 4 | 4 | 0 |
| Safety of care (infections, complications) | 3 | 5 | 0 |
| Readmissions and return visits | 4 | 7 | 0 |
Number of Medicare quality measures where this hospital’s rate is statistically better than, the same as (no different from), or worse than the national rate.
What patients said
- Doctors communicated well 3 of 5 stars
- Nurses communicated well 4 of 5 stars
- Explained medicines 2 of 5 stars
- Discharge information 4 of 5 stars
- Clean 2 of 5 stars
- Quiet at night 3 of 5 stars
From 462 patient surveys (HCAHPS), period ending 09/30/2025.
Medicare “birthing-friendly” hospital: takes part in a maternity care quality program and follows recommended safety practices.
Source: CMS Care Compare (Hospital General Information; Patient survey HCAHPS). Ratings describe the hospital overall, not individual doctors.
Physicians by specialty
- Family Medicine 339
- Internal Medicine 116
- Radiology 44
- Cardiology 44
- Anesthesiology 42
- Neurology 38
- Orthopedic Surgery 38
- OB-GYN (Obstetrics & Gynecology) 37
- General Surgery 37
- Hematology & Oncology 32
- Gastroenterology 29
- Nephrology (Kidney) 23
- Urology 21
- Hospitalist 20
- ENT (Otolaryngology) 20
- Rheumatology 20
- Geriatric Medicine 17
- Endocrinology & Diabetes 17
- Sports Medicine 15
- Neurosurgery 14
- Ophthalmology 14
- Psychiatry 13
- Dermatology 13
- Physical Medicine & Rehabilitation (PM&R) 13
- Pulmonology 13
- Vascular Surgery 12
- Pain Medicine 12
- Interventional Cardiology 11
- Heart Failure & Transplant Cardiology 11
- Pathology 10
- Cardiac Electrophysiology 9
- Infectious Disease 9
- Emergency Medicine 9
- Plastic Surgery 8
- Radiation Oncology 7
- Hand Surgery 6
- Interventional Radiology 5
- Allergy & Immunology 5
- Cardiothoracic Surgery 4
- Medical Oncology 4
- Gynecologic Oncology 4
- Spine Surgery 3
- Facial Plastic Surgery 3
- Hospice & Palliative Medicine 3
- Retina Specialist 2
- Trauma Surgery 2
- Urogynecology 2
- Hematology 2
- Pediatrics 2
- Joint Replacement Surgery 1
- General Practice 1
- Child Neurology 1
- Addiction Medicine 1
- Obesity Medicine 1
- Occupational Medicine 1
- Critical Care Medicine 1
- Colorectal Surgery 1
- Sleep Medicine 1
Other clinicians
Medical groups whose clinicians work here
- Lancaster General Medical Group 524
- Lancaster General Hospital 480
- Phoenix Rehabilitation and Health Services Inc 104
- Wellspan Medical Group 101
- Penn State Health Medical Group LLC 87
- The Heart Group of Lancaster General Health 63
- The Milton S Hershey Medical Center Physicians Group 62
- University of Penn - Medical Group 60
- Pinnacle Health Regional Physicians 51
- Lancaster Radiology Associates LTD 45
- Regional Gastroenterology Associates of Lancaster, LTD. 44
- Orthopedic Assoc of Lancaster LTD 43
- Lancaster Orthopedic Group, Inc. 33
- Pinnacle Health Medical Services 32
- Mri Group, LLP 28
Number of each group’s clinicians who list this hospital.
Industry-funded research here
Drug and device companies reported $270,951 in research payments to this hospital in 2025 for 20 studies.
- Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients
Genentech, Inc. · $37,515 - PSR-APV
Medtronic, Inc. · $36,456 - A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage…
E.r. Squibb & Sons, L.l.c. · $34,233 - A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
E.r. Squibb & Sons, L.l.c. · $29,396 · Completed - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · $26,533 · Active, not recruiting - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation · $22,024 - A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic C…
E.r. Squibb & Sons, L.l.c. · $20,350 - A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who hav…
Janssen Research & Development, LLC · $15,911 - CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. · $11,322 · Completed - Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease
Boston Scientific Corporation · $9,826 · Completed - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
Celgene Corporation · $8,065 - A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
E.r. Squibb & Sons, L.l.c. · $4,770
From CMS Open Payments research payments to this hospital as a teaching hospital. Payments to affiliated universities or research foundations are reported under those names. All industry-funded trials →
Other hospitals in the same county
Sources: CMS Hospital General Information and Doctors and Clinicians Facility Affiliation (Care Compare), CMS certification number 390100. Counts are clinicians who list this hospital with Medicare; they include part-time and visiting clinicians and aren’t staff totals. Residents and beds are from the hospital’s Medicare cost report. Ratings are Medicare’s, not ours.